Effect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation

被引:65
|
作者
Nakamae, Hirohisa [1 ]
Kirby, Katharine A. [1 ]
Sandmaier, Brenda M. [1 ,2 ]
Norasetthada, Lalita [1 ]
Maloney, David G. [1 ,2 ]
Maris, Michael B. [3 ]
Davis, Chris [1 ]
Corey, Lawrence [1 ,2 ]
Storb, Rainer [1 ,2 ]
Boeckh, Michael [1 ,2 ]
机构
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Rocky Mt Blood & Marrow Transplantat, Denver, CO USA
基金
美国国家卫生研究院;
关键词
Nonmyeloablative allogeneic hematopoietic stem cell transplantation; CMV infection; CMV diseases; BONE-MARROW-TRANSPLANTATION; TOTAL-BODY IRRADIATION; UNRELATED DONOR STATUS; CYTOMEGALOVIRUS-INFECTIONS; HEMATOLOGIC MALIGNANCIES; IMMUNOLOGICAL RECOVERY; HOST-DISEASE; RISK-FACTORS; RECIPIENTS; THERAPY;
D O I
10.1016/j.bbmt.2009.02.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nonmyeloablative conditioning is less toxic and results in initial establishment of mixed hematopoietic T cell chimerism for up to half a year with prolonged presence of host T cell immunity. In this study, we examined whether this translates into differences in the risks and/or severity of cytomegalovirus (CMV) infection and disease. We analyzed data from 537 nonmyeloablative (NM-HCT) and contemporaneous 2489 myeloablative hematopoietic cell transplant (M-HCT) recipients. In CMV seropositive recipients, no difference in the overall hazards of CMV infection at any level (adjusted hazard ratio [adj. HR] 0.9, 95% confidence interval [95% Cl]: 0.7-1.0, P=.14) was noted; however, NM-HCT was associated with a lower risk of high-grade CMV infection (adj. HR 0.7, 95% Cl: 0.5-0.9, P=.02). CMV disease rates were similar between the groups during the first 100 days after HCT, but NM-HCT recipients had an increased risk of late CMV disease (adj. HR 2.0, 95% Cl 1.2-3.4). The increased risk of late CMV disease after NM-HCT was pronounced during the earlier years of the study period, but not detectable in more recent years. Contrary to earlier reports, survival following CMV disease was not reduced after NM-HCT when compared to M-HCT recipients. These results suggest that residual host cells after NM-HCT reduce progression to higher CMV viral load in NM-HCT recipients; however, this effect does not appear to protect against serious complications of CMV. Therefore, CMV prevention strategies in NM-HCT recipients should be similar to those used in M-HCT recipients. Biol Blood Marrow Transplant 15: 694-703 (2009) (C) 2009 American Society for Blood and Marrow Transplantation
引用
收藏
页码:694 / 703
页数:10
相关论文
共 50 条
  • [1] Infectious complications following allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning regimen
    Caldera, D
    Montanari, F
    Malcovati, L
    Bernasconi, P
    Colombo, AA
    Baraté, C
    Lazzarino, M
    Alessandrino, EP
    BONE MARROW TRANSPLANTATION, 2003, 31 : S87 - S88
  • [2] Reduced-intensity conditioning allogeneic hematopoietic cell transplantation using oral fludarabine as part of the conditioning regimen
    Delgado, Julio
    Marco, Ana
    Moreno, Estela
    Pinana, Jose L.
    Valcarcel, David
    Parody, Rocio
    Sanchez-Gonzalez, Blanca
    Martino, Rodrigo
    Briones, Javier
    Sureda, Anna
    Brunet, Salut
    Sierra, Jorge
    BLOOD, 2007, 110 (11) : 306B - 306B
  • [3] Reduced-intensity conditioning allogeneic hematopoietic cell transplantation using oral fludarabine as part of the conditioning regimen
    Delgado, J.
    Marco, A.
    Moreno, E.
    Pinana, J. L.
    Valcarcel, D.
    Martino, R.
    Briones, J.
    Sureda, A.
    Brunet, S.
    Sierra, J.
    CYTOTHERAPY, 2009, 11 (03) : 356 - 361
  • [4] CMV infection and disease after allogeneic stem cell transplantation with reduced-intensity conditioning
    Avetisyan, G.
    Hagglund, H.
    Hassan, Z.
    LeBlanc, K.
    Mattsson, J.
    Ringden, O.
    Winiarski, J.
    Ljungman, P.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S241 - S242
  • [5] Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes
    Eapen, Mary
    Brazauskas, Ruta
    Hemmer, Michael T.
    Perez, Waleska S.
    Steinart, Patricia
    Horowitz, Mary M.
    Deeg, H. Joachim
    BLOOD, 2017, 130
  • [6] Allogeneic reduced intensity conditioning regimen haematopoietic stem cell transplantation
    Fürst, S
    Dubois, V
    Michallet, AS
    Nicolini, F
    Thomas, X
    Troncy, J
    Rafii, H
    Gebuhrer, L
    Michallet, M
    BONE MARROW TRANSPLANTATION, 2004, 33 : S329 - S329
  • [7] Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation
    Maffini, Enrico
    Giaccone, Luisa
    Festuccia, Moreno
    Brunello, Lucia
    Busca, Alessandro
    Bruno, Benedetto
    EXPERT REVIEW OF HEMATOLOGY, 2016, 9 (06) : 585 - 596
  • [8] The comparison of myeloablative versus reduced intensity conditioning regimen in ABO mismatched allogeneic hematopoietic cell transplantation.
    Topcuoglu, P
    Arat, M
    Bolukbasi, T
    Soydan, E
    Ozer, Y
    Ozcan, M
    Gorman, G
    Demirer, T
    Akan, H
    Beksac, M
    Arslan, O
    Ilhan, O
    BLOOD, 2004, 104 (11) : 370B - 370B
  • [9] Association between conditioning regimen intensity and nutritional aspects in allogeneic hematopoietic stem cell transplantation in children and adolescents
    Lewandowski, C. G.
    Daudt, L. E.
    Jochims, A. M. K.
    Mello, E. D.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S350 - S350
  • [10] Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia
    Nagler, Arnon
    Peczynski, Christophe
    Dholaria, Bhagirathbhai
    Labopin, Myriam
    Valerius, Thomas
    Dreger, Peter
    Kroeger, Nicolaus
    Reinhardt, Hans Christian
    Finke, Juergen
    Franke, Georg-Nikolaus
    Ciceri, Fabio
    Verbeek, Mareike
    Blau, Igor Wolfgang
    Bornhaeuser, Martin
    Spyridonidis, Alexandros
    Bug, Gesine
    Bazarbachi, Ali
    Schmid, Christophe
    Yakoub-Agha, Ibrahim
    Savani, Bipin N.
    Mohty, Mohamad
    BONE MARROW TRANSPLANTATION, 2022, 57 (07) : 1116 - 1123